Kingmed Diagnostics(603882)2025-01-24 10:40Financial Performance - The company expects a net profit attributable to shareholders for 2024 to be between -350 million and -450 million yuan, indicating a loss compared to the previous year[3]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between -155 million and -225 million yuan[4]. - In the previous year, the total profit was 740.29 million yuan, with a net profit attributable to shareholders of 643.38 million yuan[6]. - There are no significant uncertainties affecting the accuracy of this earnings forecast[9]. - The forecast data is preliminary and subject to change upon the official release of the 2024 annual report[10]. Operational Developments - The company plans to recognize credit impairment losses of approximately 650 million to 720 million yuan due to extended collection periods for some accounts receivable[7]. - The company has made significant progress in optimizing product structure and launched specialized products in infection, oncology, blood, and reproductive fields[7]. - The first on-market transaction of a medical testing data product was completed at the Guangzhou Data Exchange, marking a milestone in the third-party medical testing industry in China[7]. - The company aims to enhance internal operational management and leverage digital intelligence to drive innovation and cost efficiency[8]. - The company will continue to focus on the medical testing sector while adhering to long-termism and innovation as core development philosophies[8].